LINC01852 inhibits the tumorigenesis and chemoresistance in colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM.

"Declarations Ethics approval and consent to participateThe study was approved by the Clinical Research Ethics Committees of Affiliated Hospital of Jiangnan University, and written informed consent was obtained from all patients (LS2021102). All animal experiments were performed in accordance with the relevant institutional and national guidelines and the regulations of Jiangnan University Medical Experimental Animal Care Commission (JN. No20220415b0760906 [119]). Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This study was partially supported by grants from the National Natural Science Foundation of China (81802469, 82173063 and 81972220), the Natural Science Foundation of Jiangsu Province (BK20231144), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Committee (BJ2023057 and HB2020044), Wuxi Medical Key Discipline (ZDXK2021002), and Wuxi Taihu Lake Talent Plan, Supports for Leading Talents in Medical and Health Profession."